flex mako muscl strong end
continu pt
reiter buy rate rais pt follow
stryker strong end result top street revenue
ep expect top-lin perform driven organ growth
medsurg neurotech spine y/i respect
combin record mako sale upward inflect util
mako analysi page gm weak spot
perspect off-set solid expens management view organ
revenue growth guidanc allay concern syk top-
line durabl even tough comp ep
guidanc ep pois grow
floor mid-point expect share move higher reflect
total perform guidanc management commentari
project confid healthi capit order pipelin npi
market recon growth strategi bolster growth
mako dynam strong note record mako
placement quarter us ou
competit implant account in-lin prior quarter
procedur grew q/q knee
instal unit competit approv forthcom
feel domin posit domest
intern given grow bodi clinic evid outsiz
sale forc futur applic addit hard tissu recon
integr track management note sale forc
integr progress expect senior leadership
place territori quickli establish expect global
sale align complet end describ
portfolio highli complementari exist product
strong addit call deform print implant
valuat rate buy pt base
mo ep estim risk discuss
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
spotlight mako
part impress quarterli perform mako came well
ahead expect unit placement util robot
system sale record especi strong placement seen
ou procedur perform system reach quarter
push util new high y/i
origin forecast point break ride robot wave orthoped page
mako placement util base demand curv
intuit surgic lavin neutral experienc da vinci surgic
system placement continu trend lower da vinci expect
due narrow indic mako util mako system
surpass da vinci system quarter sequenti
y/i growth came mako essenti trend line da
vinci util curv sinc acquir asset believ
import mileston mako histori support bullish view
util track significantli higher time especi consid
add subsequ indic spine shoulder
figur histor project util
strong quarter significantli shift entir curv upward
believ sever factor could allow even
upsid estim first addit new indic spine
shoulder expand surgic base mako second increas
cementless knee adopt aid util implant
seem greater traction system third describ
call intern mako base somewhat lag us base term
regulatori approv unit gain approv perform full
rang mako-cap procedur could continu upsid
report result overal revenu came
beat btig consensu expect
respect organ revenu growth expect
back strong organ perform medsurg neurotech
segment report orthopaed revenu beat
btig consensu expect beat
driven strong result trauma divis notabl mako
sale slightli off-set miss sale estim
knee hip divis mako unit place quarter
us prior year quarter us
medsurg revenu beat btig consensu
expect respect strength
endoscopi medic healthi new product launch physio-
neurotechnolog spine revenu behind btig estim
ahead consensu estim miss driven
miss estim neurotechnolog spine divis
note though street model may reflect benefit
quarter
gross margin adjust behind estim adj
sg percentag revenu came top expect
 versu expect adj
ebit margin squar line expect told
adjust ep quarter versu btig/consensu estim
call
made follow chang model
management issu organ revenu growth guidanc within
orthopaed tweak growth expect slightli higher
trauma reflect improv perform segment
quarter within medsurg increas expect growth
endoscopi medic improv perform
launch next gener camera follow within
neurotechnolog spine kept estim in-lin previou
expect management indic neurotechnolog difficult
comp growth may moder told organ growth
actualsbtig estimate variancetot net bpssg spend bpsr spend bpsebit bpsebitda bpstax bpssourc btig research estim compani filingsvari
expect move report revenu
well off-set higher previous
 tweak gm expect sg
revenu revenu reflect
stryker perform told adj om in-lin
management om expans lower interest payment
assumpt reflect current run-rat averag left
tax-rat larg unchang per management guidanc told adj ep
estim move previou expect lastli
introduc estim model
stryker rate buy pt previous base
month adjust ep estim believ stryker
consist execut market organ growth improv margin
profil warrant premium valuat multipl peer risk relat
rate pt includ acquisit proceed expect acquisit
limit om growth increas competit robot softer market
btig research estim compani filingsnewold chang
incom etot y/i sale special oper incom incom tax expens net incom share net incom share gross oper expens btig research estim compani report
revenu y/i q/q mixdomest btig research estim compani report
btig cover compani mention report
appendix analyst certif import disclosur
